Literature DB >> 7662120

Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter.

M B Powell1, P Hyman, O D Bell, A Balmain, K Brown, D Alberts, G T Bowden.   

Abstract

The tyrosinase promoter has been used to target expression of the mutated human T24 Ha-ras oncogene in pigment-producing cells of transgenic mice. Two independent founder mice carrying the transgene survived and showed the same distinct phenotype of mutated coat color, deeply pigmented skin with multiple nevi, and twirling behavior. The offspring of one of these founders were developed into a line that stably expressed the same phenotype. Histopathological analysis of the tissues revealed hyperpigmentation and/or melanocytic hyperplasia in the skin, eyes, inner ear, and meningeal membranes in the brain. Reverse transcriptase-polymerase chain reaction analysis revealed expression of the transgene in skin, brain, and spleen. We propose that these transgenic mice will be a model for studying the process of multistage melanoma carcinogenesis and a system for evaluating potential chemopreventive agents.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7662120     DOI: 10.1002/mc.2940120205

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  19 in total

1.  UVB induces atypical melanocytic lesions and melanoma in human skin.

Authors:  E S Atillasoy; J T Seykora; P W Soballe; R Elenitsas; M Nesbit; D E Elder; K T Montone; E Sauter; M Herlyn
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

2.  Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation.

Authors:  Damia Tormo; Aleix Ferrer; Evelyn Gaffal; Jörg Wenzel; Etiena Basner-Tschakarjan; Julia Steitz; Lukas C Heukamp; Ines Gütgemann; Reinhard Buettner; Marcos Malumbres; Mariano Barbacid; Glenn Merlino; Thomas Tüting
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 3.  Model Systems for the Study of Malignant Melanoma.

Authors:  Randal K Gregg
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Activated ras. Yet another player in melanoma?

Authors:  M Herlyn; K Satyamoorthy
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

5.  Tumor vascularity and hematogenous metastasis in experimental murine intraocular melanoma.

Authors:  H E Grossniklaus
Journal:  Trans Am Ophthalmol Soc       Date:  1998

6.  p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Authors:  Tamara Terzian; Enrique C Torchia; Daisy Dai; Steven E Robinson; Kazutoshi Murao; Regan A Stiegmann; Victoria Gonzalez; Glen M Boyle; Marianne B Powell; Pamela M Pollock; Guillermina Lozano; William A Robinson; Dennis R Roop; Neil F Box
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

7.  Pigmented uveal tumours in a transgenic mouse model.

Authors:  T R Kramer; M B Powell; M M Wilson; J Salvatore; H E Grossniklaus
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

Review 8.  Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development.

Authors:  Yarí E Marín; Suzie Chen
Journal:  J Mol Med (Berl)       Date:  2004-08-21       Impact factor: 4.599

Review 9.  Authenticating cell lines in ophthalmic research laboratories.

Authors:  Robert Folberg; Shrihari S Kadkol; Shahar Frenkel; Klara Valyi-Nagy; Martine J Jager; Jacob Pe'er; Andrew J Maniotis
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-08       Impact factor: 4.799

10.  Modeling the behavior of uveal melanoma in the liver.

Authors:  Robert Folberg; Lu Leach; Klara Valyi-Nagy; Amy Y Lin; Marsha A Apushkin; Zhuming Ai; Vivian Barak; Dibyen Majumdar; Jacob Pe'er; Andrew J Maniotis
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-07       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.